12 IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY

F. Poordad, J.-P. Bronowicki, Stuart C. Gordon, +11

Journal of Hepatology

HepatologyHepatitis CViral HepatitisImmunologyAntiviral Response +9

1399 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333 +RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS

F. Poordad, E. Läwitz, K.V. Kowdley, +9

Journal of Hepatology

Viral HepatitisImmunodeficienciesImmunologyAntiviral Drug DevelopmentHepatitis +7

3 SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/− RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY

K.V. Kowdley, E. Läwitz, F. Poordad, +12

Journal of Hepatology

Viral HepatitisAntiviral Drug DevelopmentAntiviral TherapyHepatitisVirology +4

104 BOCEPREVIR (B) COMBINATION THERAPY IN NULL RESPONDERS (NR): RESPONSE DEPENDENT ON INTERFERON RESPONSIVENESS

E. Schiff, F. Poordad, Ira M. Jacobson, +15

Journal of Hepatology

ImmunologyAntiviral ResponseAntiviral Drug DevelopmentAntiviral TherapyAntiviral Drug +4

13 A 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R, ABT-072, AND RIBAVIRIN WAS WELL TOLERATED AND ACHIEVED SUSTAINED VIROLOGIC RESPONSE IN 91% TREATMENT-NAIVE HCV IL28B-CC GENOTYPE-1-INFECTED SUBJECTS

E. Läwitz, F. Poordad, K.V. Kowdley, +8

Journal of Hepatology

Viral HepatitisImmunologyAntiviral TherapyHepatitisVirology +6

1419 A RANDOMIZED TRIAL COMPARING RIBAVIRIN DOSE REDUCTION VERSUS ERYTHROPOIETIN FOR ANEMIA MANAGEMENT IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC HEPATITIS C RECEIVING BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN

F. Poordad, E.J. Lawitz, K. Rama Reddy, +16

Journal of Hepatology

HepatologyViral HepatitisHematologyAntiviral TherapyHepatitis +3

484 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Stefan Zeuzem, John M. Vierling, Rafael Esteban, +7

Journal of Hepatology

Viral PersistenceImmunodeficienciesAntiviral Drug DevelopmentAntiviral TherapyHepatitis +6

11 SUSTAINED VIROLOGIC RESPONSE (SVR) IN PRIOR PEGINTERFERON/RIBAVIRIN (PR) TREATMENT FAILURES AFTER RETREATMENT WITH BOCEPREVIR (BOC)-+-PR: THE PROVIDE STUDY INTERIM RESULTS

J.-P. Bronowicki, Mitchell Davis, S. Flamm, +15

Journal of Hepatology

In Prior Peginterferon/ribavirinAntiviral TherapyVirologyPharmacotherapyAntiviral Drug +2

ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis

Graham R. Foster, Edward Gane, Armen Asatryan, +15

Journal of Hepatology

HepatologyViral HepatitisPlus DaclatasvirAntiviral TherapyHepatitis +4

476 ANEMIA DURING TREATMENT WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN WITH OR WITHOUT BOCEPREVIR IS ASSOCIATED WITH HIGHER SVR RATES: ANALYSIS OF PREVIOUSLY UNTREATED AND PREVIOUS-TREATMENT-FAILURE PATIENTS

Mark Sulkowski, F. Poordad, M.P. Manns, +10

Journal of Hepatology

Viral HepatitisImmunodeficienciesHematologyAntiviral TherapyHepatitis +3